🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Protalix BioTherapeutics, Inc. PLX R2KPHARMA

Healthcare · Biotechnology · United States
https://www.protalix.com
Company Profile ↓
$2.67
+65.84% 1Y
Mkt Cap$215.13M
P/E14.05
P/B2.95
52W High$3.15
52W Low$1.48
Book Value$0.83
EPS (TTM)$0.19

Company Overview

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 27.3%, reflecting efficient use of shareholder capital.

Steady Revenue Expansion

Revenue has grown at a 35.9% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 14.1, below the sector median of 25.2.

Healthy Margins

Maintains a net profit margin of 20.1%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.13.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $52.74M (-1.2% YoY); net profit $-6.60M.
  • Trailing 12 Months Year-on-year growth — revenue +233.7%, earnings -325.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 35.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:35.94%
1 Year:233.70%

Compounded Profit Growth

5 Years:-
1 Year:-325.24%

Stock Price Performance

1 Year:+65.84%
6 Months:+1.91%
3 Months:+34.17%
1 Month:+9.43%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 71% of range
$1.48 $3.15
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)65.68 · Neutral
Price Performance
1M+9.43%
3M+34.17%
6M+1.91%
1Y+65.84%
Valuation vs Sector

P/E of 14.05 is below the sector median of 25.17 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 27.3%.
  • Excellent profit margin of 20.1%.
  • Compounding revenue at 35.9% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
14.05
Industry PE
25.17
Forward P/E
4.31
PEG Ratio
-
Book Value
$0.83
Price to Book
2.95
P/S
2.59
EV/EBITDA
7.30
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
35.94%
Profit 5Y
-
Revenue (YoY)
233.70%
Earnings (YoY)
-325.24%

Profitability & Returns

ROCE
-9.85%
ROE
27.27%
ROA
14.04%
Profit Margin
20.07%
Op Margin
62.65%
Gross Margin
45.24%
EPS (Latest Qtr)
$0.22
EPS (TTM)
$0.19

Balance Sheet & Liquidity

Debt/Equity
0.13
Quick Ratio
1.97
Current Ratio
3.15
Debt
$8.48M
Total Assets
$102.34M
Current Assets
$86.36M
Working Capital
$40.16M

Ownership

Promoter Holding
3.88%
Chg in Prom Hold
-
FII / Inst Holding
18.36%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$215.13M
Total Revenue (TTM)
$76.38M
EBITDA
$21.31M
Free Cash Flow
$6.78M
Operating Cash Flow
$15.09M
Shares Outstanding
80.57M
Gross Margin
45.24%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PLX Protalix BioTherapeutics, Inc. R2KPHARMA 2.67 14.05 $215.13M 0.00% -9.85% 27.27% 35.94% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 2.28M6.70M2.42M2.40M1.69M1.34M1.34M679.00K1.77M4.67M2.89M6.36M7.53M4.55M2.01M663.00K-10.44M12.25M14.25M-21.65M10.97M10.79M11.32M6.43M12.05M16.09M8.75M14.18M9.59M35.08M10.35M3.75M13.47M17.96M10.11M15.66M17.85M33.75M
Gross Profit 1.77M3.31M1.08M1.91M1.41M1.11M1.11M156.00K94.00K422.00K801.00K835.00K1.46M1.63M-177.00K-1.25M------------------------
Operating Income -5.64M-6.47M-5.45M-6.21M-5.38M-5.58M-5.00M-7.86M-9.93M-6.65M-6.37M-10.80M-7.76M-5.15M-6.74M-3.74M-3.67M-5.53M-5.84M-1.54M2.20M4.69M-2.24M-2.58M-3.71M-9.17M-1.89M-1.87M-5.52M-3.12M-2.46M20.42M-1.89M-4.86M-2.43M3.99M-4.14M1.17M2.13M21.15M
Net Income -5.75M-7.34M-6.12M-8.01M-5.97M-5.07M-3.82M-8.60M-10.85M-7.29M-59.15M450.00K-11.44M-7.24M-8.46M-5.32M-5.43M-7.26M-7.74M-3.56M291.00K1.67M-4.15M-4.44M-5.47M-11.24M-4.20M-2.29M-5.33M-3.57M-3.13M19.34M-1.85M-4.59M-2.20M3.24M-3.62M164.00K2.35M18.32M
Diluted EPS ---------0.11---0.06---0.06---------0.14-0.14-0.25-0.09-0.05-0.11-0.07-0.050.21-0.04-0.06-0.030.03-0.050.000.030.22
R&D Expense 7.72M8.15M7.08M8.05M6.10M6.02M5.07M7.33M10.01M6.35M5.97M9.30M7.12M7.29M7.48M10.07M-11.70M13.32M10.00M-10.34M9.19M7.69M7.12M7.69M7.28M8.77M7.58M7.39M5.85M4.47M3.67M2.89M2.96M3.00M3.48M5.99M4.47M5.43M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 388.00K6.64M8.39M34.87M03.52M4.36M9.20M21.08M34.24M54.69M62.90M38.35M47.64M65.49M53.40M52.74M
Gross Profit -3.19M6.86M1.44M26.28M02.89M3.63M801.00K4.01M--------
Operating Income -31.97M-29.97M-36.53M-12.17M-34.06M-28.56M-23.67M-33.16M-34.52M-19.31M-10.72M2.71M-20.46M-13.01M10.46M3.92M-5.50M
Net Income -31.44M-29.00M-36.53M-11.62M-27.79M-29.94M58.04M-29.36M-83.44M-26.46M-18.28M-6.52M-27.58M-14.93M8.31M2.93M-6.60M
Diluted EPS -----------1.23-0.22-0.62-0.310.090.04-0.08
R&D Expense 27.39M37.69M37.82M36.66M29.23M27.35M24.89M30.41M32.17M33.33M44.62M38.17M29.73M29.35M17.09M12.97M19.57M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --64.73M51.80M78.73M113.33M78.36M97.25M82.25M72.21M61.13M45.39M67.93M-55.79M84.43M73.42M82.35M
Current Assets --------------44.88M69.93M60.08M66.67M
Cash & Equivalents 42.60M81.27M35.90M27.00M52.03M86.40M54.77M76.37M63.28M51.16M37.81M17.79M18.27M-17.11M23.63M19.76M14.68M
Inventory --------------16.80M19.05M21.24M25.73M
Receivables --------------4.59M5.27M2.91M8.84M
Total Liabilities --76.05M77.88M82.08M140.28M133.96M86.38M92.20M101.67M114.01M115.71M94.97M-66.43M50.87M30.21M34.12M
Current Liabilities --18.90M18.69M25.75M26.70M64.35M11.23M66.21M22.75M25.35M40.17M86.47M-32.43M45.53M25.62M26.52M
Long Term Debt ---6.57M5.42M2.37M912.00K------27.89M28.19M---
Total Debt --------------33.47M26.28M5.53M8.32M
Total Equity 44.35M15.88M-11.32M-26.08M-3.36M-26.95M-55.60M10.87M-9.96M-29.46M-52.88M-70.32M-27.04M--10.64M33.57M43.21M48.23M
Shares Outstanding --------------53.79M72.95M75.85M80.43M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 44.45M-38.46M-23.57M635.00K-30.65M-29.28M-24.28M-32.10M-9.99M-7.74M-19.36M-26.11M--25.00M-1.32M8.67M-11.99M
Investing Cash Flow -6.17M-7.99M-5.87M-2.29M-2.10M-1.00M39.39M-967.00K-1.12M-591.00K-883.00K-19.95M--5.04M-16.71M4.22M-2.37M
Financing Cash Flow 293.00K501.00K20.93M26.56M--6.63M19.70M-1.42M-4.75M046.47M-8.24M24.67M-16.79M9.33M
Capital Expenditure -6.20M-7.86M-5.71M-2.07M-1.89M-785.00K-464.00K-849.00K-971.00K-686.00K-627.00K-655.00K--628.00K-1.15M-1.28M-1.64M
Free Cash Flow 38.26M-46.32M-29.27M-1.43M-32.54M-30.07M-24.75M-32.95M-10.96M-8.43M-19.98M-26.76M--25.63M-2.47M7.39M-13.63M
Net Change in Cash --------------21.80M6.64M-3.90M-5.03M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -821.4%103.3%17.2%75.4%-82.1%83.3%8.7%19.0%--------
Operating Margin % -8,239.4%-451.2%-435.6%-34.9%--810.6%-542.4%-360.5%-163.8%-56.4%-19.6%4.3%-53.4%-27.3%16.0%7.3%-10.4%
Net Margin % -8,103.1%-436.6%-435.6%-33.3%--849.9%1,329.9%-319.2%-395.9%-77.3%-33.4%-10.4%-71.9%-31.3%12.7%5.5%-12.5%
ROE % -197.9%256.1%140.1%346.1%103.1%53.9%533.8%294.9%283.3%50.0%26.0%24.1%-140.3%24.8%6.8%-13.7%
ROCE % --65.4%-110.3%-23.0%-39.3%-203.9%-27.5%-206.8%-69.8%-54.0%-205.4%-14.6%--55.7%26.9%8.2%-9.9%

Shareholding Pattern

Insiders
3.88%
Institutions
18.36%
Public Float
19.09%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 5.02% 4.05M $10.28M
2 Renaissance Technologies, LLC 1.36% 1.10M $2.78M
3 State Street Corporation 1.22% 983.58K $2.50M
4 Geode Capital Management, LLC 1.22% 980.00K $2.49M
5 Northern Trust Corporation 1.14% 922.34K $2.34M
6 Vanguard Portfolio Management LLC 0.63% 510.64K $1.30M
7 Stratos Wealth Partners, Ltd. 0.62% 500.00K $1.27M
8 Dimensional Fund Advisors LP 0.61% 493.42K $1.25M
9 Goldman Sachs Group Inc 0.59% 475.92K $1.21M
10 Marshall Wace LLP 0.56% 452.76K $1.15M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PLX

Google News Fri, 04 Sep 2026

Director at Protalix BioTherapeutics (PLX) gets new options and stock units - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNT2tMS09xdUNWQmNSR0RVZGQ1aUJnaGFlOS1RcWVvbTc0TkhkMkUydkoyLWxDZ3hlUzdWemJvem04a3ZEWUd4dzVGV0w5MFU0cDdrS01NZlQ5dk40RV90UEtBNVNMcWlpMmlyRVhLWmNCc2NHNDdJVlJkM0VVVTZIQjc5TWRJWDFLM3VsVn…

Google News hu, 13 Aug 2026

Protalix (PLX) Stock Profit Swing Sharpens Focus On Elfabrio Reliance - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQNzUtakg5dHQyNkV3VHRseFNURkc2OURoaWdKbFhxRlpxS3NMU2VydWZMODhiWU80RGV3ZHdpNlVwaTM0d0pvTlFMbUhLMWVnSS1udTRIcDVvZGo3bTh4VUJNWUpjcWpJbzA3TGNwVGJVSk1ZZk50SmRQWDh0LXIwT3FpNFZkZ2R6OUpoTm…

Google News Fri, 04 Sep 2026

Protalix (NYSE: PLX) sets CEO equity to 3-year vesting, change-in-control terms - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOczQ1cmpNM1Y5a0ZCSUJqdnh1OFJCamRsRHNQeHFxM0F3YWp5TlJWZWVVeXRzYlZBN0xYZlVhY3F5TDU2UVV1d3dOZFYwa2JhZWV4R0ZQOUxZNjQwZXd2TUVEcUV6UEZHV2phdmpPekVWT3BiMTEzRXB1MGNfWTdvVG5OMzRMWFdFLUJOSU…

Google News Wed, 13 May 2026

$PLX ($PLX) Releases Q1 2026 Earnings | PLX Stock News - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPM19IUEQ0OTZlcjRJSXI4MnZPc3R6TjdsTndwNGFOMVNyNW5TWWlPWGhKSko5US1FRVlueHdkUzdqN21wUUJ2ZVZ6LVZrWENhc0doYVlqVTBoUzh1Q3hSRTNBUDlLbXlscmp3dzZwVS0zaGRsVWd6c3liSmhzQlhpbFp2X0g?oc=5" targ…

Google News Wed, 12 Aug 2026

Protalix (PLX) Stock Profit Swing Sharpens Focus On Elfabrio Reliance - webull.com

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9MTkZockVEb0lSMlVMOWotV09zbDJ2RDZlUkJtVlpoaUgyYzlnTFVIREVaZWdmdDRZMWs5U2VEYnFsNzdFSFdfQTZ6TkhSS3pnYU9jcWxzc1Q?oc=5" target="_blank">Protalix (PLX) Stock Profit Swing Sharpens Focus…

Google News hu, 05 Mar 2026

PLX Shares Jump 13% On EMA Committee’s Turnaround On New Dosing Regimen For Fabry Disease Therapy - Stocktwits

<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNU1RxTXJlVG8tNDJNSko4LXY0SUxjc0QwRzdHd2UzcTBtZ05pREFEZENtZzVHcjRUaGo0cHFZb2w3SnlNYjJBV1JtbkVxb19vZjhkdjV5YzdnNkROdF9iT2VvVjVPSzJMYWIzcDc2eEpSRjRKdFFFRm5oenVfZEJPTGJ2TlpFZjdwcGQwej…

PLX — Frequently Asked Questions

What is the current share price of Protalix BioTherapeutics, Inc. (PLX)?

As of 2026-09-07 16:24 PDT, Protalix BioTherapeutics, Inc. (PLX) trades at $2.67 on NYSE American. Its 52-week range is $1.48 to $3.15.

What is the market capitalisation of PLX?

Protalix BioTherapeutics, Inc. (PLX) has a market capitalisation of $215.13M on NYSE American.

What is the P/E ratio of PLX?

PLX trades at a trailing price-to-earnings (P/E) ratio of 14.05. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.95.

What is the return on equity (ROE) of PLX?

PLX has a return on equity (ROE) of 27.27%. Its return on capital employed (ROCE) is -9.85%.

Is PLX a good stock to buy?

This page provides a data-driven analysis of Protalix BioTherapeutics, Inc. (PLX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space